Compare BRBS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | CABA |
|---|---|---|
| Founded | 1893 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.1M | 319.6M |
| IPO Year | 2015 | 2019 |
| Metric | BRBS | CABA |
|---|---|---|
| Price | $3.33 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 200.9K | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | 10.26 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $329.00 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.23 | $1.26 |
| 52 Week High | $4.79 | $4.23 |
| Indicator | BRBS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 39.92 |
| Support Level | $3.23 | $3.12 |
| Resistance Level | $3.33 | $3.48 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 80.00 | 17.56 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.